Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

About this update from Zhejiang East Asia Pharmaceutical Co., Ltd. Class A

Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Zhejiang East Asia Pharmaceutical Co., Ltd. Class A